Medical Equipment

Lipid Panel Testing Market Expansion Outlook: $16.27 Billion by 2029 Forecast

November 17, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

#What Is The Projected Market Size Of The Lipid Panel Testing Market By 2029?

The overall scope of cholesterol panel examination witnessed robust expansion lately, projected to escalate from a valuation of $10.88 billion in the year 2024 to $11.61 billion come 2025, reflecting a steady compounded annual growth rate of 6.7% over that span; this notable upward trajectory during the past phase is fundamentally linked to a rising prevalence of heart and blood vessel ailments, heightened public consciousness regarding proactive wellness measures, supportive governmental endeavors aimed at cardiac well-being, shifts in typical ways of living and eating habits, coupled with the increasing proportion of elderly individuals and the corresponding rise in long-term health conditions.

Anticipated robust expansion characterizes the coming years for the market encompassing lipid panel testing; specifically, this sector is projected to attain a valuation of $16.27 billion by the year 2029, driven by an estimated compound annual growth rate (CAGR) of 8.8%. Key factors fueling this upward trajectory through the projection timeframe encompass the rising emphasis on genetic diagnostics and bespoke medical approaches, a heightened concentration on identifying conditions proactively and preempting them, the broader availability of testing solutions intended for at-home use, a shift toward healthcare reimbursement structures centered on demonstrable value, and intensified screening protocols within demographics identified as particularly susceptible. Regarding predominant market dynamics expected during this future period, noteworthy developments include the proliferation of testing conducted directly at the site of care, increased confluence with standardized electronic health record systems, the evolution of genetic assessments specifically targeting lipids, the growing adoption of self-administered testing apparatuses, the incorporation of remote medical consultation services, and intensified educational campaigns centered around effective lipid control strategies.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10270&type=smp

Which Factors And Drivers Are Influencing The Lipid Panel Testing Market In 2025?

Anticipation surrounds the lipid panel testing market’s upward trajectory, fueled by the rising prevalence of both cardiovascular ailments and diabetes. Cardiovascular conditions represent a collection of disorders impacting the heart and circulatory system, while diabetes is a metabolic dysfunction characterized by inadequate insulin production, resulting in elevated glucose concentrations. Lipid panel analysis serves as a crucial diagnostic measure for pinpointing those at elevated danger of acquiring heart disease or those already affected by it; moreover, this testing validates the efficacy of ongoing care for patients managing established cardiovascular or diabetic conditions, enabling medical professionals to refine therapeutic strategies to meet specified lipid benchmarks and mitigate subsequent health risks. Illustratively, as reported by the World Health Organization, a United Nations specialized body headquartered in Switzerland, cardiovascular diseases were responsible for 17.9 million fatalities as of September 2023. Correspondingly, data from the Centers for Disease Control and Prevention (CDC), a US governmental entity, indicated in its 2022 National Diabetes Statistics Report that the count of diabetes diagnoses across the United States climbed to 37.3 million that same year. Consequently, the growing burden of both heart disease and diabetes is set to propel the expansion of the lipid panel testing sector.

How Is The Lipid Panel Testing Market Segmented?

The lipid panel testingmarket covered in this report is segmented –

1) By Product And Services: Devices, Kits, Services

2) By Prescription Mode: Prescription-Based Testing, OTC-Based Testing

3) By Application: Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hypo-Lipoproteinemia, Tangier Disease, Atherosclerosis, Other Applications

4) By End User: Hospital, Specialty Clinics And Physician Offices, Pathology Laboratories, Diagnostic Clinics, Ambulatory Surgical Centers, Reference Laboratories, Academic And Research Institutes, Other End-Users

Subsegments:

1) By Devices: Automated Analyzers, Point-Of-Care Testing Devices, Spectrophotometers

2) By Kits: Test Kits For Cholesterol, HDL And LDL Kits, Triglyceride Test Kits

3) By Services: Laboratory Testing Services, Diagnostic Services, Health Screening Services

Which Trends Are Impacting The Lipid Panel Testing Market?

A significant trend currently captivating the market for lipid panel testing revolves around advancements in product offerings, wherein major industry players are concentrating their efforts on engineering novel solutions to solidify their competitive standing. Illustratively, in October of 2022, the American biotechnology firm Boston Heart Diagnostics launched LipoMap, which constitutes the most thorough commercial array of assessments for lipid metabolism, incorporating a panel of 33 distinct tests spanning lipids, lipoproteins, and apolipoproteins, a development designed to expose reversible and treatable lipid irregularities implicated in cardiovascular disease (CVD), thereby facilitating more tailored therapeutic strategies and subsequent monitoring.

Which Leading Companies Dominate The Lipid Panel Testing Market Share?

Major companies operating in the lipid panel testing market include Abbott Laboratories, Beckman Coulter Inc., F. Hoffmann-La Roche Ltd., Randox Laboratories Ltd., Thermo Fisher Scientific Inc., PTS Diagnostics, Quest Diagnostics Incorporated, Alere Inc., EuroMedix International, Boston Heart Diagnostics Corporation, Eurofins Scientific SE, Spark Diagnostics Pvt Ltd., Everlywell Inc., Horiba ABX SAS, Siemens Healthcare GmbH, Nova Biomedical Corporation, Bio-Rad Laboratories Inc., Danaher Corporation, DiaSorin S.p.A., EKF Diagnostics Holdings plc, Grifols S.A., Hologic Inc., Luminex Corporation, Meridian Bioscience Inc., Ortho Clinical Diagnostics LLC

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/lipid-panel-testing-global-market-report

How Does The Lipid Panel Testing Market Perform Across Key Geographic Regions?

North America was the largest region in the lipid panel testing market in 2024. Asia-Pacific is expected to be the fastest growing region in the global lipid panel testing market during the forecast period. The regions covered in the lipid panel testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The Lipid Panel Testing Market Report:

https://www.thebusinessresearchcompany.com/customise?id=10270&type=smp

Browse Through More Reports Similar to the Global Lipid Panel Testing Market 2025, By The Business Research Company

Chemicals Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chemicals-global-market-report

Ethylene Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/ethylene-global-market-report

Genetically Modified Crops Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/genetically-modified-crops-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795